Best Peptides for Longevity & Anti-Aging: An Honest, Evidence-Graded Ranking

Key takeaways

• No peptide has been shown to extend human life or slow human aging. Not one. Any ranking that says otherwise is ranking marketing.
• Ranked by what has actually happened in human trials, the top of the list is not a "longevity peptide" at all: semaglutide reduced heart attacks, strokes and cardiovascular deaths by 20% in 17,604 adults with obesity and heart disease, and tirzepatide matched an active comparator on the same outcomes in 13,299 people with diabetes. Those are the only hard-outcome data any peptide has.
• Below them sit compounds with human surrogate data (tesamorelin for visceral fat, sermorelin for growth hormone and IGF-1, NAD+ precursors for blood NAD+) and then compounds with mouse, cell or unblinded data (epitalon, MOTS-c, humanin).
• Legality sorts the list a second time. In October 2026 a US pharmacy can dispense semaglutide, tirzepatide, tesamorelin, sermorelin and NAD+; it cannot compound thymosin alpha-1, epitalon or MOTS-c, and elamipretide is a prescription drug for one ultra-rare disease. Vials sold for the rest are unapproved drugs.
• The honest "best longevity peptide" for most adults is the one that treats a condition they actually have, prescribed by a clinician who measures something, not a stack bought on the promise of more years.

How we ranked

We graded each compound on the evidence for a longevity-relevant outcome in humans using the site's A to D scale: A for adequately powered randomized trials or meta-analyses, B for limited human trials, C for surrogate or observational human data, D for animal, cell or no data. We then sorted by legality in the United States as of October 2026, using our legal tracker, because a compound no pharmacy may prepare has no legal version to recommend. Safety and cost break ties; popularity did not enter the ranking.

One framing point: "longevity" in a human trial means fewer deaths or fewer of the events that cause them, measured over years in thousands of people. Only two drugs on this list have been tested that way, and neither trial enrolled healthy people. A grade describes the evidence for a specific claim, not a recommendation: tesamorelin carries an A for visceral fat in HIV lipodystrophy and a D for living longer, and the table shows both.

The ranking at a glance

Costs are from our cost guide as of October 9, 2026.

1. Semaglutide: the only peptide with a longevity-adjacent outcome trial

What it does. Semaglutide is a GLP-1 receptor agonist: it lowers appetite, slows the stomach and improves glucose handling. In obesity trials it produces about 15% weight loss at 68 weeks; the numbers are in our GLP-1 guide.

The key trial. SELECT enrolled 17,604 adults aged 45 or older with a BMI of 27 or more and established cardiovascular disease but no diabetes, randomized to semaglutide 2.4 mg weekly or placebo for a mean follow-up of 39.8 months. The primary endpoint, cardiovascular death, non-fatal heart attack or non-fatal stroke, occurred in 6.5% on semaglutide and 8.0% on placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90); discontinuations for adverse events were twice as common on semaglutide (16.6% versus 8.2%) (Lincoff 2023).

Grade and caveats. A, and the strongest evidence on this page. It is not a longevity trial: participants already had heart disease, the endpoint was cardiovascular events rather than death from any cause, and it says nothing about healthy 40-year-olds. It is, however, the only demonstration that a peptide reduces the events that end lives.

Legal status and cost. FDA-approved (Ozempic, Wegovy, Rybelsus). Compounded copies are legal only for a patient with a documented need the approved product cannot meet, and FDA sent 55 warning letters to telehealth companies in 2026 over their marketing. Brand Wegovy is $349 a month for cash patients; compounded versions run $150 to $350.

Who it is for. Adults with obesity, especially with cardiovascular disease, diabetes or related conditions. Not a drug for lean people chasing longevity.

2. Tirzepatide: more weight loss, a different kind of outcome trial

What it does. A single peptide that activates both the GLP-1 and GIP receptors. It produces the largest weight loss of any approved medication, about 21% at the 15 mg dose at 72 weeks in SURMOUNT-1; see the GLP-1 guide.

The key trial. SURPASS-CVOT randomized 13,299 people with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide up to 15 mg or dulaglutide 1.5 mg weekly, an active comparator already shown to reduce cardiovascular events. The primary endpoint occurred in 12.2% on tirzepatide and 13.1% on dulaglutide, a hazard ratio of 0.92 (95.3% CI 0.83 to 1.01): non-inferior, but not superior, to dulaglutide (Nicholls 2025).

Grade and caveats. A. Because the comparator was an effective drug rather than placebo, the trial shows that tirzepatide protects the heart at least as well as a proven GLP-1 drug in diabetes; it does not quantify the benefit against doing nothing. No placebo-controlled cardiovascular outcome trial of tirzepatide in obesity without diabetes has reported yet.

Legal status and cost. Approved (Mounjaro, Zepbound); compounding restricted as for semaglutide since the shortage ended in December 2024. Brand Zepbound costs $299 to $449 a month by dose; compounded, $180 to $300.

Who it is for. The same population as semaglutide, where more weight loss is the goal.

3. Tesamorelin: proven on a surrogate, in a specific population

What it does. Tesamorelin is a stabilized analog of growth hormone-releasing hormone that reduces visceral (deep abdominal) fat, the fat depot most tied to metabolic disease.

The key trial. In 412 HIV-infected adults with abdominal fat accumulation, tesamorelin 2 mg daily for 26 weeks reduced visceral fat by about 15% versus a small increase on placebo, with improvements in triglycerides and no clinically meaningful change in glucose; IGF-1 rose substantially (Falutz 2007). Later work in the same population showed a modest reduction in liver fat.

Grade and caveats. A for visceral fat in HIV-associated lipodystrophy, the approved indication; D for aging, since no trial has used it in healthy older adults and the fat returns when it is stopped. It raises IGF-1, which carries the same cancer caution as sermorelin below.

Legal status and cost. Approved as Egrifta; off-label use is a prescriber's decision. Because FDA regulates tesamorelin as a biological product, no pharmacy may compound it, so the brand, at $2,400 to $2,800 a month, is the only legal version; the 'compounded tesamorelin' some clinics sell is not made under a compounding exemption FDA recognizes. Details in the tesamorelin profile and the cost guide.

Who it is for. Adults with HIV lipodystrophy and, off-label, people with documented visceral obesity who know they are using a metabolic tool, not a longevity drug.

4. Sermorelin: raises the hormones, not the outcomes

What it does. The first 29 amino acids of growth hormone-releasing hormone, which prompts the pituitary to release growth hormone in its natural pulses.

The key trial. In the longest placebo-controlled study of a sermorelin-class analog, 19 adults aged 55 to 71 injected a GHRH analog nightly at 10 micrograms per kilogram for 16 weeks; growth hormone output rose 70 to 107% and IGF-1 rose about 28%, in both women and men (Khorram 1997). Strength, body composition and sleep changes across the sermorelin trials were small or inconsistent, and no trial measured an aging outcome.

Grade and caveats. B for raising growth hormone and IGF-1 at adequate doses; D for longevity. The caution is the mechanism: higher circulating IGF-1 is associated with a modestly increased risk of common cancers, with odds ratios of about 1.5 for prostate cancer and 1.65 for premenopausal breast cancer comparing the 75th with the 25th percentile across 21 studies (Renehan 2004). That is an association in people taking no drug, but it is why a clinician should measure IGF-1 and not push it past the normal range. The sermorelin profile covers the growth hormone trials in healthy elderly people: fluid retention, joint pain and glucose problems, no functional gain.

Legal status and cost. Compoundable (formerly approved as Geref); $150 to $400 a month through telehealth, with the common clinic doses several times lower than the studied ones.

Who it is for. Symptomatic adults with documented low IGF-1, under monitoring. Not anyone buying "anti-aging".

5. NAD+ precursors and NAD+ injections: a biomarker that moves, outcomes that do not

What they do. Nicotinamide riboside and NMN are vitamin B3 derivatives that raise NAD+, a coenzyme central to energy metabolism and DNA repair. NAD+ itself is also compounded for injection and infusion; it is not a peptide, as the NAD+ profile explains.

The key trials. The positive one: in 25 postmenopausal women with prediabetes who were overweight or obese, NMN 250 mg a day for 10 weeks increased muscle insulin sensitivity on a clamp study while placebo did not (Yoshino 2021). The negative one: in NOPARK, 410 people with early Parkinson's disease took nicotinamide riboside 1,000 mg a day or placebo for a year, and symptom scores were 2.72 points worse on the precursor (Brakedal 2026). Meta-analyses of the smaller trials find no effect on weight, glucose, lipids or muscle function.

Grade and caveats. B for raising NAD+ reliably; C for the insulin-sensitivity signal; D for aging. Infused NAD+ is broken down before cells can take it up, and no study has tested NAD+ injections against an outcome. In 2024 FDA warned that some compounders were making injectable NAD+ from food-grade powder; a recall followed in 2025.

Legal status and cost. NR and NMN are legal supplements (NMN's status was restored in September 2025). NAD+ injections are compounded under FDA's interim Category 1 policy, with a 2019 proposal to exclude it unfinalized; $105 to $350 a month for injections, $250 to $1,500 per IV session.

Who it is for. Someone who wants to run a cheap oral experiment with modest expectations. Not someone paying for drips.

6. Thymosin alpha-1: a real drug abroad, unavailable here, untested for aging

What it does. A 28-amino-acid thymic peptide that modulates immune function, sold outside the US as thymalfasin (Zadaxin).

The key trial. In 98 patients with chronic hepatitis B, thymosin alpha-1 1.6 mg subcutaneously twice a week for 26 weeks produced a complete virological response in 40.6% at 18 months versus 9.4% in untreated controls, with histological improvement and no significant side effects (Chien 1998). Reviews describe approvals in more than 35 countries for hepatitis B and C and use as a vaccine adjunct; newer antivirals have since made the hepatitis uses largely obsolete.

Grade and caveats. B for hepatitis B; D for aging. The idea that restoring thymic signaling slows immune aging is plausible and untested; a 1989 placebo-controlled study in elderly men examined it only as a flu-vaccine adjunct, and the 2003 Russian mortality report (see epitalon, below) used a bovine thymic extract, not thymosin alpha-1.

Legal status and cost. Not approved in the US, where it holds orphan-drug designations only (which are not approvals). FDA placed it in Category 2 in September 2023, its committee reviewed it in December 2024, and FDA proposes not to add it to the 503A list, so no pharmacy may compound it; see the tracker.

Who it is for. Nobody in the US, legally.

7. GHK-Cu: skin, topically, and only that

What it does. A naturally occurring copper-binding tripeptide that, in cell and animal work, stimulates collagen and wound repair; in skincare it is used for fine lines, firmness and texture.

The evidence. The human data are small cosmetic studies, many unpublished or industry-run, summarized in a 2018 review by the peptide's discoverer, whose company sells it (Pickart 2018). They report modest improvements in skin appearance over weeks to months. There are no human data on injected GHK-Cu and nothing on aging beyond the skin.

Grade and caveats. C for skin appearance; D for everything else, with the grade reflecting the conflict of interest and the study sizes as much as the results.

Legal status and cost. Topical GHK-Cu is a legal cosmetic without drug claims; injectable GHK-Cu came off FDA's Category 2 list in April 2026, awaits committee review by February 2027 and cannot be compounded. Retail skincare pricing; details in the GHK-Cu profile.

Who it is for. Anyone who wants a reasonable skincare ingredient with modest expectations.

8. Epitalon: the longevity peptide with the longest story and the thinnest proof

What it does. Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide designed in St Petersburg from epithalamin, a pineal gland extract. It is sold as a telomerase activator and lifespan extender.

The evidence. Three layers, each weaker than sellers imply. In cell culture, the developers reported telomerase activation in fetal fibroblasts. In mice, 54 females injected with 1 microgram of epitalon five days a month from the age of 3 months lived no longer on average than controls; the last 10% of survivors lived 13.3% longer, maximum lifespan was 12.3% longer and leukemia was less common, while total tumor incidence was unchanged (Anisimov 2003). In humans, the developers reported that 266 elderly people given thymalin (a thymic extract) and epithalamin (the pineal extract, not synthetic epitalon) for two to three years had mortality 1.6- to 2.5-fold lower than controls over 6 to 8 years, and 4.1-fold lower in a subgroup treated yearly; the abstract mentions no randomization, blinding or placebo, and the authors developed the products (Khavinson 2003).

Grade and caveats. D. A mouse study with no mean-lifespan effect and an unblinded report by the manufacturer of a different preparation are not evidence that epitalon extends human life, and no independent group has tested it. Its FDA nomination proposed it for insomnia, not aging.

Legal status and cost. Not compoundable. It was on Category 2 from September 2023, came off on April 15, 2026, and FDA's advisory committee voted 7-4-1 on July 24, 2026 to recommend it against FDA staff advice; no rule has issued.

Who it is for. Nobody, until a trial exists.

9. MOTS-c: good mouse biology, zero human trials

What it does. A 16-amino-acid peptide encoded in mitochondrial DNA that activates AMPK; in mice it improves insulin sensitivity, prevents diet-induced obesity and improves endurance in old age.

The evidence. The late-life mouse study is the one sellers quote: 22-month-old mice given 15 mg/kg a day ran about twice as long, and intermittent treatment from 23.5 months improved grip, gait and glucose, with a lifespan trend that was not significant (P = 0.23). In humans, intense exercise raised muscle MOTS-c about 12-fold in 10 young men, and that is the entirety of the human data (Reynolds 2021). The only human trial in the family tested a modified analog, CB4211, for four weeks in 20 people; no phase 2 followed.

Grade and caveats. D. FDA's reviewers found no human data at all when its committee considered it in July 2026.

Legal status and cost. Not compoundable: committee vote 7-5-2 on July 23, 2026, rule pending. The vials sold online are unapproved drugs. Full detail in the MOTS-c profile.

Who it is for. Nobody, legally or evidentially.

10. SS-31 (elamipretide): an approved mitochondrial drug that is not a longevity product

What it does. Elamipretide binds cardiolipin in the inner mitochondrial membrane and is the first mitochondria-targeted drug to reach the US market.

The evidence. In September 2025 FDA granted elamipretide (Forzinity) accelerated approval to improve muscle strength in patients with Barth syndrome, an ultra-rare genetic disease, weighing at least 30 kg, on the basis of knee-extensor strength as an intermediate endpoint, with a confirmatory trial required (Shirley 2026). In the broader population it was tried in, the result was negative: in MMPOWER-3, 218 adults with primary mitochondrial myopathy received 40 mg a day subcutaneously or placebo for 24 weeks, and neither six-minute walk distance nor fatigue improved (Karaa 2023).

Grade and caveats. A for its approved use, on a surrogate; D for aging, where there are mouse muscle data and nothing in people. The negative myopathy trial is the closest human test of the "mitochondrial rejuvenation" idea, and it failed.

Legal status and cost. A prescription drug dispensed through a specialty pharmacy for one disease. The "SS-31" sold online is a research vial; FDA named SS-31 in its August 24, 2026 warning letters to five vendors, and no telehealth program legitimately offers it for longevity.

Who it is for. Patients with Barth syndrome.

11. Humanin: the original mitochondrial peptide, still preclinical

What it does. A 24-amino-acid peptide encoded in the mitochondrial 16S rRNA gene, discovered before MOTS-c and studied for neuroprotection and metabolism.

The evidence. Overexpressing humanin extended lifespan in worms; a potent analog given twice weekly to middle-aged mice improved metabolic healthspan markers; humanin levels generally fall with age across species but stay stable in the naked mole-rat, and children of centenarians have higher circulating humanin than age-matched controls (Yen 2020). No human has received humanin in a trial.

Grade and caveats. D. Interesting biology, with the same CohBar-linked authorship as the MOTS-c work.

Legal status and cost. No approved or compoundable product exists anywhere. Vials sold online are research chemicals.

What we excluded and why

• Human growth hormone. A protein, not a peptide in the marketing sense, and distributing it for anti-aging is a federal crime under 21 U.S.C. 333(e). In healthy elderly people it produced about 2 kg less fat and 2 kg more lean mass, no functional benefit, and more swelling, joint pain, carpal tunnel and glucose problems; the sermorelin profile has the detail.
• BPC-157 and TB-500. Marketed for healing, not longevity; no human trials, and neither can be compounded in 2026 despite the July committee votes. See the legal tracker.
• CJC-1295 and ipamorelin. Growth hormone secretagogues with almost no adult human data; FDA's committee voted against both in late 2024.
• 5-amino-1MQ. Not a peptide, and no human trials.
• Collagen peptides. A food supplement digested like any protein.
• Rapamycin, metformin, senolytics. Not peptides; a different conversation.
• FOXO4-DRI, Klotho, thymalin, GDF11 and the rest of the gray-market list. Preclinical, unavailable, or both.

How to get it

The only peptides on this list with a legal path are the ones with a condition attached. For semaglutide or tirzepatide, that means a prescription from a clinician licensed in your state and, in 2026, usually the brand product through the manufacturer programs or the federal TrumpRx listings; compounded versions require a documented individual need. For sermorelin, telehealth providers prescribe compounded versions filled by a named 503A pharmacy; tesamorelin is legal only as the brand Egrifta, which cannot be compounded. A legitimate prescriber of either measures IGF-1 before and during treatment. For NAD+, oral precursors need no prescription; injections do, and the pharmacy should state its legal basis and ingredient grade.

Everything from thymosin alpha-1 down has no legal version in the United States: a clinic offering epitalon, MOTS-c or humanin is selling research vials, and the price buys no label, no testing and no accountability. Our cost guide lists the seven questions to ask before paying for any of it.

Bottom line

Ranked honestly, the best peptides for longevity are drugs for obesity and its consequences, because those are the only peptides anyone has tested against the events that shorten life. Below them are hormone-axis peptides that move a biomarker and ask you to assume the rest, then a coenzyme that is not a peptide, then a cosmetic, then molecules with mouse data and no legal product. None has been shown to slow human aging, and the two with the loudest longevity marketing, epitalon and MOTS-c, have no controlled human trial of any aging, disease or sleep outcome: MOTS-c itself has never been tested in people, and epitalon's only placebo-controlled study measured a urine melatonin marker (epitalon profile).

If you are deciding whether to pay for a "longevity peptide" in 2026, the useful question is not which one but which condition. If you have one that a peptide treats, treat it, with monitoring. If you do not, keep your money and go for a run; that, at least, raises your MOTS-c.

Frequently asked questions

+−What is the best peptide for longevity?

If 'best' means the strongest human evidence for living longer or avoiding the diseases that shorten life, the answer is semaglutide, a GLP-1 peptide: in the SELECT trial of 17,604 adults with obesity and cardiovascular disease, it cut heart attacks, strokes and cardiovascular deaths by 20% over about three years. That is a cardiovascular result in a high-risk population, not a longevity trial in healthy people, and no peptide has one of those. Every peptide marketed specifically for longevity, from epitalon to MOTS-c, has either mouse data, cell data or small unblinded reports.

+−Are longevity peptides legitimate?

The science behind several of them is legitimate; the products mostly are not. MOTS-c and humanin are real mitochondrial peptides studied in good laboratories, and epitalon has a long Russian literature. What none of them has is a human trial showing any aging outcome, and in October 2026 none can be legally compounded in the United States. A vial sold as a longevity peptide is an unapproved drug with no verified content, bought on the strength of animal experiments.

+−What is the downside of taking peptides?

It depends entirely on which one. Approved peptide drugs such as semaglutide have known side-effect profiles (nausea, gallbladder disease, muscle loss with rapid weight loss) and large safety databases. Hormone-axis peptides such as compounded sermorelin and brand tesamorelin raise growth hormone and IGF-1, which brings fluid retention, joint pain, glucose effects and a cancer-growth caution. Research vials carry the biggest downside: no sterility or potency testing, no clinician, and no legal recourse when something goes wrong.

+−What are the top 5 peptides to take?

There is no list of five peptides a healthy adult should take. Ranked by evidence and legality, the five with a defensible case for some use are semaglutide and tirzepatide (obesity and its cardiovascular consequences), tesamorelin (visceral fat, with a drug approval behind it), sermorelin (restoring growth hormone output in adults with low IGF-1, with monitoring) and topical GHK-Cu (skin, modestly). None of them is a longevity drug, and the right question is which condition you are treating, not which peptides to stack.

+−What are the differences between epitalon and sermorelin?

Sermorelin is a fragment of growth hormone-releasing hormone with an FDA approval history, human trials showing it raises growth hormone and IGF-1, and a legal compounding path. Epitalon is a synthetic four-amino-acid peptide designed from a Russian pineal extract, with cell-culture reports of telomerase activation, a mouse study that did not change mean lifespan, and human reports from its developers that were not blinded or randomized; no US pharmacy may compound it. One is a prescribable hormone secretagogue with modest effects; the other is a research chemical with a longevity story.

+−Do peptides really help aging skin?

Topical peptides, chiefly GHK-Cu, have small cosmetic studies showing modest improvements in fine lines, firmness and skin texture over weeks to months, and they are legal as cosmetics. Injected longevity peptides have no skin data at all. Tretinoin, sunscreen and, where appropriate, hormone therapy have far stronger evidence for skin aging than any peptide.

+−What is the best peptide for anti-aging?

For the appearance of aging skin, topical GHK-Cu is the only peptide with a legal product and some human evidence. For the diseases of aging, the GLP-1 peptides have the outcome trials. For aging itself, no peptide has been shown to slow it in humans, and the two mitochondrial peptides sold for that purpose, MOTS-c and humanin, have never been given to a person in a trial.

+−Do peptides actually work for anti-aging?

Not in the sense the phrase implies. No peptide, and no drug of any kind, has been shown in a human trial to slow biological aging or extend lifespan. What some peptides do is treat conditions that accelerate aging: semaglutide reduces cardiovascular events in people with obesity, tesamorelin removes visceral fat, and sermorelin raises growth hormone output in people whose levels are low. Calling those anti-aging is marketing; calling them treatments for specific problems is accurate.

+−What peptide will make you look younger?

Topically, GHK-Cu and similar signal peptides can modestly improve skin texture and fine lines. No injected peptide has been shown to change how old a person looks. Growth hormone secretagogues are sometimes sold for skin and hair, and no trial supports that use; the one thing growth hormone reliably changes in healthy older adults is fluid retention, which can make a face look fuller for a while.

Sources

1. StudyLincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-32. (2023)
2. StudyNicholls SJ et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med 2025;393:2409-20. (2025)
3. StudyFalutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357:2359-70. (2007)
4. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
5. ReviewRenehan AG et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53. (2004)
6. StudyYoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021;372:1224-9. (2021)
7. StudyBrakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA 2026 (published online October 8, 2026). (2026)
8. StudyChien RN et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998;27:1383-7. (1998)
9. StudyAnisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003;4:193-202. (2003)
10. StudyKhavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003;24:233-40. (2003)
11. StudyReynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021;12:470. (2021)
12. ReviewShirley M. Elamipretide: first approval. Drugs 2026;86:377-83 (accelerated approval for Barth syndrome granted in September 2025). (2026)
13. StudyKaraa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology 2023;101:e238-52. (2023)
14. ReviewPickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19:1987. (2018)
15. StudyYen K et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY) 2020;12:11185-99. (2020)